You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Polynitroxylated Pegylated Hemoglobin for Traumatic Brian Injury Resuscitation

    SBC: SYNZYME TECHNOLOGIES LLC            Topic: 102

    DESCRIPTION provided by applicant Traumatic brain injury TBI is a leading cause of morbidity and mortality especially when complicated by secondary insults such as hypotension Vulnerability of TBI patients to hypotension is well recognized and identifies a key need for new approaches The goal of this proposal is to develop to IND a neuroprotective hyper colloid oxygen therapeutic polynit ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. A high resolution and high DQE detector optimized for mammography using single shot bi directional tri contrast imaging

    SBC: SIGRAY, INC.            Topic: NIBIB

    DESCRIPTION provided by applicant X ray tricontrast imaging provides three different modes of contrast absorption contrast the mechanism behind how conventional medical X ray imaging equipment images phase contrast which provides up to X more contrast than absorption based contrast for soft tissue and scatter contrast which provides information of features at dimensions smaller than ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a small molecule activator of integrin cell adhesion to enhance therapeutic responses to checkpoint blockade in cancer

    SBC: 7 Hills Pharma LLC            Topic: 102

    DESCRIPTION provided by applicant Recent FDA approvals of ipilimumab nivolumab and pembrolizumab which target checkpoint receptors cytotoxic T lymphocyte associated antigen CTLA and programmed death PD have ushered in a new era of cancer immunotherapy in metastatic melanoma Despite unprecedented overall survival benefits with combination therapy the incidence of complete respo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Assay System and Analysis Algorithm in Detecting RNA Editing Events and Linked Splicing Isoforms

    SBC: Celetrix LLC            Topic: NIDA

    Abstract RNA editing is a process in which the genome encoded information is altered in RNA RNA editing is an efficient way to increase RNA complexity thereby fine tuning both gene function and dosage Adenosine to Inosine A to I editing is the most common type of RNA editing known in animals The cellular machinery recognizes inosine as guanosine so A to I editing of codons and splicing sign ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics

    SBC: Waldron International llc            Topic: NIDA

    DESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants

    SBC: PARABON NANOLABS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There is a critical need for a safe and effective vaccine against HIV Decades of work have been invested in understanding the immune response to infection and different approaches have been taken to develop vaccines that are effective in preventing and treating the disease While effective in animal models none have been as effective in humans The immune ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of the Production and Isolation of the Novel Antifungal Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have als ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. development of immunodeficient rabbit models

    SBC: Celetrix LLC            Topic: NIAID

    DESCRIPTION provided by applicant Transplantation of human or animal pluripotent stem cells PSCs or their derivatives to model animals constitutes an important preclinical system to model and investigate cell survival development and differentiation in vivo and to assess the safety and efficacy of transplantation based cell therapies Immunodeficient mice are dominantly used in biomedical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government